Loxo Oncology Inc (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $96.57, for a total value of $1,448,550.00. Following the sale, the chief executive officer now directly owns 190,207 shares in the company, valued at approximately $18,368,289.99. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Shares of Loxo Oncology Inc (NASDAQ LOXO) opened at $104.80 on Friday. The company has a market capitalization of $3,123.98, a P/E ratio of -17.98 and a beta of 2.57. Loxo Oncology Inc has a 52 week low of $40.01 and a 52 week high of $108.50.
Several large investors have recently made changes to their positions in the company. Sands Capital Management LLC purchased a new stake in Loxo Oncology in the 4th quarter valued at approximately $191,266,000. BlackRock Inc. lifted its stake in Loxo Oncology by 20.6% in the 2nd quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock valued at $128,534,000 after buying an additional 273,291 shares in the last quarter. OppenheimerFunds Inc. lifted its stake in Loxo Oncology by 62.8% in the 4th quarter. OppenheimerFunds Inc. now owns 1,061,111 shares of the biopharmaceutical company’s stock valued at $89,324,000 after buying an additional 409,209 shares in the last quarter. Vanguard Group Inc. lifted its stake in Loxo Oncology by 24.7% in the 2nd quarter. Vanguard Group Inc. now owns 914,719 shares of the biopharmaceutical company’s stock valued at $73,351,000 after buying an additional 181,471 shares in the last quarter. Finally, Lord Abbett & CO. LLC lifted its stake in Loxo Oncology by 372.0% in the 2nd quarter. Lord Abbett & CO. LLC now owns 739,540 shares of the biopharmaceutical company’s stock valued at $59,304,000 after buying an additional 582,862 shares in the last quarter.
Several equities research analysts have recently commented on the company. BidaskClub raised Loxo Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Zacks Investment Research raised Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Citigroup reissued a “buy” rating and set a $112.00 price target (up previously from $86.00) on shares of Loxo Oncology in a research note on Friday, October 20th. Ifs Securities raised Loxo Oncology from an “outperform” rating to a “strong-buy” rating in a research note on Tuesday, November 14th. Finally, JMP Securities raised Loxo Oncology from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $77.18 to $95.00 in a research note on Tuesday, November 14th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Loxo Oncology has a consensus rating of “Buy” and an average price target of $97.33.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/17/loxo-oncology-inc-loxo-ceo-sells-1448550-00-in-stock.html.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.